Download PDF
Journal of Pediatric Neurology 2022; 20(06): 386-391
DOI: 10.1055/s-0042-1749588
Original Article

Improved Sitting Balance in Children with Cerebral Palsy: Body Functions to Activity and Participation

Merve Akyuz 
1   Department of Physical Medicine and Rehabilitation, Bursa State Hospital, Turkey
,
Nigar Dursun 
2   Department of Physical Medicine and Rehabilitation, Kocaeli University Faculty of Medicine, Izmit/Kocaeli, Turkey
,
Tugba Gokbel 
2   Department of Physical Medicine and Rehabilitation, Kocaeli University Faculty of Medicine, Izmit/Kocaeli, Turkey
,
Cigdem Cekmece 
2   Department of Physical Medicine and Rehabilitation, Kocaeli University Faculty of Medicine, Izmit/Kocaeli, Turkey
,
Erbil Dursun 
2   Department of Physical Medicine and Rehabilitation, Kocaeli University Faculty of Medicine, Izmit/Kocaeli, Turkey
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

The aim of this study is to evaluate the changes in activity and participation domains of International Classification of Functioning (ICF), Disability and Health, in children with cerebral palsy (CP) who received integrated botulinum toxin A (BoNT-A) treatment with intensive rehabilitation with a treatment goal of improved sitting balance. In this prospective observational study, 29 patients with CP (mean age: 6.7 ± 3.8 years) and the Gross Motor Function Classification System (GMFCS) levels of IV and V were included. The primary outcome measures were the mean changes from baseline to posttreatment weeks 10 to 12 of the Child and Adolescent Scale of Participation (CASP) and Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD). The modified Ashworth scale (MAS) and Tardieu scale (TS) results at 6 to 8 weeks of posttreatment were the secondary outcome measures. Statistically significant improvements in home and community participation of CASP (p < 0.001 and 0.001), CPCHILD (p < 0.01), MAS (p < 0.001), and all parameters of TS (p < 0.05) were recorded after treatment. The result of this prospective, observational study showed that the functional improvements in sitting balance by the integrated BoNT-A treatment provides positive effects on activity and participation levels of the patient and quality of life of patients and their families.

Keywords

cerebral palsy - botulinum toxin-A - sitting balance - activity - participation


Publication History

Received: 27 February 2022

Accepted: 20 April 2022

Article published online:
27 June 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Rosenbaum P, Paneth N, Leviton A, Goldstein M, Bax MA. Report: the definition and classification of CP in the definition and classification of cerebral palsy. Dev Med Child Neurol 2007; 109: 8-14
    PubMedGoogle Scholar
  • 2 Cans C. Surveillance of Cerebral Palsy in Europe. Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Surveillance of Cerebral Palsy in Europe (SCPE). Dev Med Child Neurol 2000; 42 (12) 816-824
    CrossrefPubMedGoogle Scholar
  • 3 Dursun N, Gokbel T, Akarsu M, Dursun E. Randomized controlled trial on effectiveness of intermittent serial casting on spastic equinus foot in children with cerebral palsy after botulinum toxin-A treatment. Am J Phys Med Rehabil 2017; 96 (04) 221-225
    CrossrefPubMedGoogle Scholar
  • 4 Dursun N, Gokbel T, Akarsu M, Bonikowski M, Pyrzanowska W, Dursun E. Intermittent serial casting for wrist flexion deformity in children with spastic cerebral palsy: a randomized controlled trial. Dev Med Child Neurol 2021; 63 (06) 743-747
    CrossrefPubMedGoogle Scholar
  • 5 Dursun N, Akyuz M, Gokbel T, Akarsu M, Karacan C, Dursun E. Long term improvement on GMFCS level of patients with cerebral palsy treated by an integrated approach of repeated botulinum toxinA injections. Dev Med Child Neurol 2019; 61 (S3): 175
    PubMedGoogle Scholar
  • 6 Novak I, Morgan C, Fahey M. et al. State of the evidence traffic lights 2019: systematic review of interventions for preventing and treating children with cerebral palsy. Curr Neurol Neurosci Rep 2020; 20 (02) 3
    CrossrefPubMedGoogle Scholar
  • 7 Mathevon L, Bonan I, Barnais JL, Boyer F, Dinomais M. Adjunct therapies to improve outcomes after botulinum toxin injection in children: a systematic review. Ann Phys Rehabil Med 2019; 62 (04) 283-290
    CrossrefPubMedGoogle Scholar
  • 8 Yana M, Tutuola F, Westwater-Wood S, Kavlak E. The efficacy of botulinum toxin A lower limb injections in addition to physiotherapy approaches in children with cerebral palsy: a systematic review. NeuroRehabilitation 2019; 44 (02) 175-189
    CrossrefPubMedGoogle Scholar
  • 9 Fonseca Jr. PR, Calhes Franco de Moura R, Galli M, Santos Oliveira C. Effect of physiotherapeutic intervention on the gait after the application of botulinum toxin in children with cerebral palsy: systematic review. Eur J Phys Rehabil Med 2018; 54 (05) 757-765
    CrossrefPubMedGoogle Scholar
  • 10 Salazar AP, Pagnussat AS, Pereira GA, Scopel G, Lukrafka JL. Neuromuscular electrical stimulation to improve gross motor function in children with cerebral palsy: a meta-analysis. Braz J Phys Ther 2019; 23 (05) 378-386
    CrossrefPubMedGoogle Scholar
  • 11 Jackman M, Novak I, Lannin N. Effectiveness of hand splints in children with cerebral palsy: a systematic review with meta-analysis. Dev Med Child Neurol 2014; 56 (02) 138-147
    CrossrefPubMedGoogle Scholar
  • 12 Register ACPR. Australian Cerebral Palsy Register Report 2018. Accessed May 3, 2022 at: https://cpregister.com/wp-content/uploads/2019/02/Report-of-the-Australian-Cerebral-Palsy-Register-Birth-Years-1995-2012.pdf
    PubMedGoogle Scholar
  • 13 Delgado MR, Tilton A, Russman B. et al. AbobotulinumtoxinA for equinus foot deformity in cerebral palsy: a randomized controlled trial. Pediatrics 2016; 137 (02) e20152830
    CrossrefPubMedGoogle Scholar
  • 14 Farag SM, Mohammed MO, El-Sobky TA, ElKadery NA, ElZohiery AK. Botulinum toxin a injection in treatment of upper limb spasticity in children with cerebral palsy: a systematic review of randomized controlled trials. JBJS Rev 2020; 8 (03) e0119
    CrossrefPubMedGoogle Scholar
  • 15 Blumetti FC, Belloti JC, Tamaoki MJ, Pinto JA. Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy. Cochrane Database Syst Rev 2019; 10 (10) CD001408
    PubMedGoogle Scholar
  • 16 Bleyenheuft Y, Ebner-Karestinos D, Surana B. et al. Intensive upper- and lower-extremity training for children with bilateral cerebral palsy: a quasi-randomized trial. Dev Med Child Neurol 2017; 59 (06) 625-633
    CrossrefPubMedGoogle Scholar
  • 17 Sakzewski L, Bleyenheuft Y, Boyd RN. et al. Protocol for a multisite randomised trial of Hand-Arm Bimanual Intensive Training Including Lower Extremity training for children with bilateral cerebral palsy: HABIT-ILE Australia. BMJ Open 2019; 9 (09) e032194
    CrossrefPubMedGoogle Scholar
  • 18 Naidu K, Smith K, Sheedy M, Adair B, Yu X, Graham HK. Systemic adverse events following botulinum toxin A therapy in children with cerebral palsy. Dev Med Child Neurol 2010; 52 (02) 139-144
    CrossrefPubMedGoogle Scholar
  • 19 Papavasiliou AS, Nikaina I, Foska K, Bouros P, Mitsou G, Filiopoulos C. Safety of botulinum toxin A in children and adolescents with cerebral palsy in a pragmatic setting. Toxins (Basel) 2013; 5 (03) 524-536
    CrossrefPubMedGoogle Scholar
  • 20 Copeland L, Edwards P, Thorley M. et al. Botulinum toxin A for nonambulatory children with cerebral palsy: a double blind randomized controlled trial. J Pediatr 2014; 165 (01) 140-146.e4
    CrossrefPubMedGoogle Scholar
  • 21 Swinney CM, Bau K, Burton KLO, O'Flaherty SJ, Bear NL, Paget SP. Severity of cerebral palsy and likelihood of adverse events after botulinum toxin A injections. Dev Med Child Neurol 2018; 60 (05) 498-504
    CrossrefPubMedGoogle Scholar
  • 22 Bonikowski M, Sławek J. Safety and efficacy of Botulinum toxin type A preparations in cerebral palsy - an evidence-based review. Neurol Neurochir Pol 2021; 55 (02) 158-164
    CrossrefPubMedGoogle Scholar
  • 23 Hoare BJ, Wallen MA, Imms C, Villanueva E, Rawicki HB, Carey L. Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE). Cochrane Database Syst Rev 2010; 1 (01) CD003469
    PubMedGoogle Scholar
  • 24 Dursun N, Bonikowski M, Dabrowski E. et al. Efficacy of repeat abobotulinumtoxinA (Dysport) injections in improving gait in children with spastic cerebral palsy. Dev Neurorehabil 2020; 23 (06) 368-374
    CrossrefPubMedGoogle Scholar
  • 25 Tilton A, Russman B, Aydin R. et al. AbobotulinumtoxinA (Dysport(R)) improves function according to goal attainment in children with dynamic equinus due to cerebral palsy. J Child Neurol 2017; 32 (05) 482-487
    CrossrefPubMedGoogle Scholar
  • 26 Sahoo R, Rege S, Rao S. Social participation in children with cerebral palsy. Online J Health Allied Sci 2017; 16: 5
    PubMedGoogle Scholar
  • 27 Lorin K, Forsberg A. Treatment with botulinum toxin in children with cerebral palsy: a qualitative study of parents' experiences. Child Care Health Dev 2016; 42 (04) 494-503
    CrossrefPubMedGoogle Scholar